Loading…
Loading…
D.A. Davidson and CO. boosted its holdings in Schwab Fundamental U.S. Large Company ETF (NYSEARCA:FNDX) by 169.5% during the undefined quarter, according to its most recent disclosure with the SEC. The firm owned 25,449 shares of the company's stock after buying an additional 16,007 shares during the period. D.A. Davidson and CO.'s
The Schwab Fundamental U.S. Large Company ETF is upgraded to buy, reflecting a less favorable macroeconomic and AI outlook. FNDX reduces mega-cap bias by weighting holdings on fundamentals—revenue, operating cash flow, dividends, and net buybacks—rather than market capitalization. This approach results in a less concentrated portfolio, offering diversification benefits compared to traditional broad market index funds.
The arrival of June usually signals a seasonal slowdown for many people, but our ETF industry clearly missed the memo. Instead of heading to the beach or stopping to watch the World Cup, the ETF ecosystem had a wave of milestones, structural changing-of-the-guards, and high-profile index provider consolidation.
Looking for broad exposure to the Large Cap Value segment of the US equity market? You should consider the Schwab Fundamental U.S. Large Company ETF (FNDX), a passively managed exchange traded fund launched on August 13, 2013.
Value investing spent most of the post-2010 cycle losing to growth, but the past year has flipped that script.
Making its debut on 08/13/2013, smart beta exchange traded fund Schwab Fundamental U.S. Large Company ETF (FNDX) provides investors broad exposure to the Style Box - Large Cap Value category of the market.
Schwab Fundamental U.S. Large Company Index ETF offers a diversified, fundamentally weighted portfolio with strong value characteristics and steady dividend growth. FNDX maintains lower sector and company concentration risk than the Russell 1000, with no sector above 16% and the top issuer at 4.5%. FNDX has recently outperformed the Russell 1000 over 12 months, but since 2013, it has lagged the benchmark and trails close competitor IUS in recent returns.
Vancouver, British Columbia--(Newsfile Corp. - April 29, 2026) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D0) (the "Company" or "FendX"), a technology company developing surface-protection solutions to reduce the spread of harmful pathogens, announces that it has entered into an agreement dated April 28, 2026, with Innovotech Labs Corporation ("Innovotech") (TSXV: IOT) (OTCQB: IOTCF) to support regulatory planning for its coated catheter program. Under the agreement, Innovotech will conduct regulatory research to determine the appropriate U.S. Food and Drug Administration ("FDA") classification and regulatory pathway for FendX's coated Foley catheter product currently in development.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for FNDX and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.